Andrea Mokler - Immatics VP Sciences

IMTX Stock  USD 7.18  0.09  1.24%   

VP

Andrea Mokler is VP Sciences of Immatics NV
Address Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076
Phone49 7071 5397 0
Webhttps://www.immatics.com

Immatics Management Efficiency

The company has return on total asset (ROA) of (0.1217) % which means that it has lost $0.1217 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2432) %, meaning that it created substantial loss on money invested by shareholders. Immatics' management efficiency ratios could be used to measure how well Immatics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.3 in 2024. At this time, Immatics' Net Tangible Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 3.1 M in 2024, whereas Total Assets are likely to drop slightly above 298.3 M in 2024.
Immatics NV currently holds 15.4 M in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Immatics NV has a current ratio of 2.89, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Immatics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 5 records

VP Age

Leah JDInhibrx
N/A
Brennan DoyleHarmony Biosciences Holdings
N/A
Luke AlbrechtSyndax Pharmaceuticals
45
Luke JDSyndax Pharmaceuticals
45
Esther JDKeros Therapeutics
N/A
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 388 people. Immatics NV (IMTX) is traded on NASDAQ Exchange in USA. It is located in Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076 and employs 542 people. Immatics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Immatics NV Leadership Team

Elected by the shareholders, the Immatics' board of directors comprises two types of representatives: Immatics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immatics. The board's role is to monitor Immatics' management team and ensure that shareholders' interests are well served. Immatics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immatics' outside directors are responsible for providing unbiased perspectives on the board's policies.
PHR MBA, Director HR
Andrea Mokler, VP Sciences
Edward Sturchio, General Secretary
Arnd MBA, Chief Officer
Kristijan Lasic, Director Accounting
Miriam Meyer, VP Affairs
Toni Weinschenk, CoFounder Officer
Evelyn RothGeissler, VP Operations
Anja BSc, Director Communications
Carsten MD, Chief Officer
HansGeorg Rammensee, CoFounder Board
Steffen Walter, Chief Officer
Cedrik MD, Chief Officer
Dominik Maurer, Senior Unit
Edward JD, General Secretary
Harpreet Singh, MD, CEO
Ali Mohamed, Senior CMC
Emmanuelle MBA, VP Head
Ephraim MSc, Vice Accounting
Rainer Kramer, Chief Munich
Jordan Silverstein, Head Strategy

Immatics Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immatics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immatics Stock Analysis

When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.